You are here:Home Home>>News&Events>Highlights>

Highlights

CanSino Biotechnology Successfully Passed EU GMP Audit


On February 3-4, 2015, a team led by the Qualified Person (QP) of 


an EU pharmaceutical enterprise conducted a two-day GMP audit of


CanSino Biotechnology Inc. This GMP audit was mainly for quality 


management systems, production equipment and facilities used in 


the production of human vaccines and biological products.CanSino


Biotechnology successfully passed this audit. Through this QP audit, 


it marks that CanSino has reached a significant milestone in the 


establishment of quality systems and maintaining high quality standards 


in the development and manufacturing of vaccine and biological products. 


It is also a key step in the transition from product development to product 


commercialization.